Goralatide is a tetrapeptide regulator of hematopoiesis.1 It decreases the proportion of mouse high proliferative potential colony forming cells (HPP-CFCs) in S phase when cultured using regenerating femoral marrow conditioned medium at a concentration of 1 ng/ml. Goralatide (4 µg/kg twice per day) reduces decreases in the number of HPP-CFCs, burst-forming unit erythroid (BFU-E) cells, and colony forming unit granulocyte-macrophages (CFU-GMs) induced by 5-fluorouracil in mice.2 It also reduces mortality induced by doxorubicin in mice.3
1.Robinson, S., Lenfant, M., Wdzieczak-Bakala, J., et al.The molecular specificity of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of hematopoietic stem cell proliferationStem Cells11(5)422-427(1993) 2.Aidoudi, S., Guigon, M., Lebeurier, I., et al.In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracilBr. J. Haematol.94(3)443-448(1996) 3.MassÉ, A., Ramirez, L.H., Bindoula, G., et al.The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: Improvement in mice survival and protection of bone marrow stem cells and progenitorsBlood91(2)441-449(1998)